Back to News
Market Impact: 0.2
Calluna Pharma Completes Dosing in Phase 2 AURORA Study of CAL101 in Idiopathic Pulmonary Fibrosis and Reports Completion of Final Independent Safety Review
Source: Business Wire
Healthcare & Biotech
Calluna Pharma completed dosing in the Phase 2 AURORA study of CAL101 in idiopathic pulmonary fibrosis (IPF), and the final independent data monitoring committee review is complete. Topline results are expected in Q1 2027; no efficacy or safety findings were reported.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
More News
- J&J's 6% slide on an imperfect quarter is a gift to prospective buyers
- UnitedHealth Group tops estimates, hikes profit outlook as insurer manages high medical costs
- Liquidia (NASDAQ:LQDA) CMO Rajeev Saggar disposes of $262,528 in stock
- Rhythm Pharmaceuticals launches IMCIVREE in Japan for obesity
- J&J beats earnings estimates; Middle East conflict weighs on medical-device sales
- Johnson & Johnson shares SLIDE nearly 6% despite stronger full-year forecast
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Introducing AllMind: A New Data & AI Workspace for Institutional Investors
- AI Tools for Private Equity Due Diligence: A Buyer Workflow